Not Signed In - OrthoLogic Announces Results Of Preliminary Interim Analysis Of Phase 2b Clinical Trial Of Chrysalin(R) (TP508) In Fracture Repair
Wed, 30 Aug 2006 07:00 AM EST
... OrthoLogic Corp.(Nasdaq: OLGC) today announced results of an interim analysis of data fromits Phase 2b dose-ranging clinical trial of the novel synthetic peptideChrysalin(R) (TP508) in unstable, displaced distal radius (wrist)fractures. Study Description This was a prospective, double-blind, randomized, placebo-controlledPhase 2b multi-site, five-arm dose-response study. [click link for full article] ...
Related Topics
- Clinical Trials
- Data Analysis
- Fractures
- Ribavirin and Interferon alfa-2b, recombinant
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Interferon Alfa-2b
- Rectocele
- Peginterferon alfa-2b
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Bevacizumab Injection
- Hernia
- Crohn's Disease
- Pancreatic Cancer
- Fracture
- Brain injury that results in physical, emotional, or intellectual changes or deficits
email this page
print this page
bookmark this page
feedback on this page
